Biomarkers

Pursuing Multiple Biomarkers for Early Idiopathic Parkinson’s Disease Diagnosis

Biomarkers, Parkinson's Disease, Pre-PD /

Currently, there is no objective molecular or biochemical test for PD; its diagnosis is based on clinical criteria, mainly by cardinal motor symptoms, which manifest when patients have lost about 60–80% of dopaminergic neurons. Therefore, it is urgent to establish a panel of biomarkers for the early and accurate diagnosis of PD. Once the disease […]

Pursuing Multiple Biomarkers for Early Idiopathic Parkinson’s Disease Diagnosis Read More »

Extracellular Vesicles as Novel Diagnostic and Prognostic Biomarkers for Parkinson’s Disease

Biomarkers, Parkinson's Disease, Pre-PD /

Brain-derived EVs are able to cross the blood-brain barrier,protecting their payload from enzymatic degradation, and are easily recovered from biofluids. Interestingly, EVcontent is strongly influenced by the specific pathophysiological status of the donor cell. In this manuscript, therole of EVs as source of novel PD biomarkers is discussed, providing all recent findings concerning relevantproteins and

Extracellular Vesicles as Novel Diagnostic and Prognostic Biomarkers for Parkinson’s Disease Read More »

Olfactory dysfunction in aging and neurodegenerative diseases

Biomarkers, Dementia - Lewy Bodies, Olfactory /

The establishment of biomarkers that promote early risk identification is critical for the implementation of early treatment to postpone or avert pathological development. Olfactory dysfunction (OD) is seen in 90% of early-stage PD patients and 85% of patients with early-stage AD, which makes it an attractive biomarker for early diagnosis of these diseases. Here, we

Olfactory dysfunction in aging and neurodegenerative diseases Read More »

Temporal trajectory of biofluid markers in Parkinson’s disease

A-Synuclein, Biomarkers, Parkinson's Disease, Pre-PD /

At baseline, PD patients showed lower CSF α-syn, Aβ, t-tau and p-tau levels than those of the controls. In all PD patients, CSF α-syn and Aβ decreased in a negative exponential pattern before the onset of motor symptoms, whereas CSF t-tau and p-tau, and serum NfL increased. Patients with cognitive impairment exhibited faster decline of

Temporal trajectory of biofluid markers in Parkinson’s disease Read More »

Desulfovibrio Bacteria Are Associated With Parkinson’s Disease

Biomarkers, Gut Dysbiosis, Gut Microbiota, Hydrogen, Metabolites, Parkinson's Disease, Pre-PD /

Parkinson’s disease (PD) is the most prevalent movement disorder known and predominantly affects the elderly. It is a progressive neurodegenerative disease wherein α-synuclein, a neuronal protein, aggregates to form toxic structures in nerve cells. The cause of Parkinson’s disease (PD) remains unknown. Intestinal dysfunction and changes in the gut microbiota, common symptoms of PD, are

Desulfovibrio Bacteria Are Associated With Parkinson’s Disease Read More »

A randomised controlled trial on effectiveness and feasibility of sport climbing in Parkinson’s disease

Biomarkers, Diet and Exercise, Parkinson's Disease, Pre-PD /

Physical activity is of prime importance in non-pharmacological Parkinson’s disease (PD) treatment. The current study examines the effectiveness and feasibility of sport climbing in PD patients in a single-centre, randomised controlled, semi-blind trial. A total of 48 PD patients without experience in climbing (average age 64 ± 8 years, Hoehn & Yahr stage 2–3) were assigned either

A randomised controlled trial on effectiveness and feasibility of sport climbing in Parkinson’s disease Read More »

Gut Microbiome Changes with Osteopathic Treatment of Constipation in Parkinson’s Disease: A Pilot Study

Biomarkers, Parkinson's Disease, Pre-PD /

The gut microbiome appears to be predictive of Parkinson’s disease (PD) with constipation. Chronic constipation frequently manifests prior to motor symptoms and impairs quality of life. An osteopathic manipulative medicine (OMM) sequence used physical exam assessment and manual treatment of neuromusculoskeletal dysfunctions pertinent to constipation in PD for this prospective ABA-design study, IRB-NYITBHS1065. The effects

Gut Microbiome Changes with Osteopathic Treatment of Constipation in Parkinson’s Disease: A Pilot Study Read More »

Deciphering and manipulating the epigenome for the treatment of Parkinson’s and Alzheimer’s disease

Biomarkers, Parkinson's Disease /

This narrative review aimed to elaborate on the potential epigenomic treatments for PD and AD. About 199 scientific articles written in English, which reported on novel epigenomic-based treatment for PD and AD, were selected for this review from the PubMed database. Full articles and relevant data were extracted. Treatments targeting DNA methylation or miRNAs appear

Deciphering and manipulating the epigenome for the treatment of Parkinson’s and Alzheimer’s disease Read More »

Identification of leaky gut-related markers as indicators of metabolic health in Dutch adults: The Nutrition Questionnaires plus (NQplus) study

Biomarkers, Gut Dysbiosis, Gut Permeability / Leaky Gut, Lipopolysaccharides (LPS), Parkinson's Disease, Pre-PD, Zonulin /

Biomarkers that link a leaky gut and subsequent bacterial translocation to metabolic health were identified in this study. Especially zonulin may aid in monitoring a leaky gut and detecting individuals at risk for developing chronic metabolic diseases. CLICK TO REVIEW

Identification of leaky gut-related markers as indicators of metabolic health in Dutch adults: The Nutrition Questionnaires plus (NQplus) study Read More »

Serum metabolic biomarkers for synucleinopathy conversion in isolated REM sleep behavior disorder

A-Synuclein, Biomarkers, iRBD, Parkinson's Disease, Pre-PD /

Our results indicate that metabolic alterations and inflammation are involved in iRBD pathophysiology, and suggest biological differences underlying the progression of LTS in iRBD patients. Our data also indicate that profiling of serum samples by NMR may be a useful tool for identifying short-term high-risk iRBD patients for conversion to parkinsonism or dementia. CLICK TO

Serum metabolic biomarkers for synucleinopathy conversion in isolated REM sleep behavior disorder Read More »